Photo by lcma1028 from unsplash
ABSTRACT The medical and pharmaceutical industries must commit to full consensus on biosimilar products. Regulatory recommendations and current resources applied to biosimilars should not be squandered. Additionally, continued lessons learned… Click to show full abstract
ABSTRACT The medical and pharmaceutical industries must commit to full consensus on biosimilar products. Regulatory recommendations and current resources applied to biosimilars should not be squandered. Additionally, continued lessons learned should be applied for the preparation of future unknown classes of medical treatments. Recommendations from provider consensus are sound, logical, and feasible. These should be set forth, implemented and agreed upon globally.
Keywords:
biosimilar;
firm regulatory;
cigar biosimilar;
products firm;
close cigar;
biosimilar products
Journal Title: International Journal of Healthcare Management
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: International Journal of Healthcare Management
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!